Back Hepatitis B Hepatitis B Topics HBV Treatment

Monitoring Inactive Hepatitis B Is Cost-effective but Must Increase to Improve Survival

Lifelong monitoring of people with inactive hepatitis B virus (HBV) infection may be cost-effective, according to a study in China published the December 19 advance online edition of Hepatology. Monitoring and treatment would have to be substantially expanded, however, to achieve significant reductions in liver cancer and hepatitis B-related mortality.

alt

Read more:

Adding Pegylated Interferon to Antivirals for Hepatitis B May Lead to HBsAg Loss

Addition of pegylated interferon to nucleoside/nucleotide antivirals increases the likelihood of hepatitis B surface antigen (HBsAg) loss -- considered a cure -- in people with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B, according to a report in December 2013 edition of Journal of Clinical Virology.

alt

Read more:

AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.

alt

Read more:

AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years

Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.

alt

Read more:

AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more: